Stay informed about the latest breakthroughs in clinical research, FDA approvals, and healthcare innovation.
The FDA has approved suzetrigine, the first non-opioid pain medication for moderate-to-severe acute pain, addressing a critical need for non-addictive pain management alternatives.
Revolutionary gene-editing platforms developed by researchers are enabling custom gene editing for rare metabolic disorders, representing significant strides in genetic medicine.
A comprehensive guide to the questions you should ask and factors to consider when evaluating a clinical trial opportunity, including new FDA expedited pathways.
In 2025, the FDA approved 46 novel drugs. Learn how Phase 3 trials work and why they're the crucial final step before a treatment reaches patients.
Why diverse participation matters for medical research, how it impacts treatment outcomes, and what researchers are doing to make trials more inclusive.
Artificial intelligence is transforming how patients find clinical trials, analyzing vast datasets for personalized matching and accelerating the path to new treatments.
Several highly anticipated weight loss treatments are pending FDA approval, including oral GLP-1 drugs like orforglipron that could offer more accessible alternatives to injectables.
Yeztugo (lenacapavir), a revolutionary twice-yearly injectable for HIV pre-exposure prophylaxis (PrEP), has been approved, offering a significant advancement in AIDS prevention.
New Phase 2a trial uses focused ultrasound to temporarily open the blood-brain barrier, enabling immunotherapy (pembrolizumab) to reach glioblastoma tumors. Actively recruiting at Northwestern University Chicago and other major US centers.
A new Phase 1/2 trial (NCT06097832) is recruiting at 5 major US academic centers to test NXC-201, a BCMA-targeted CAR-T cell therapy, in relapsed/refractory AL amyloidosis. Learn about the trial design, key eligibility, site locations, and how Corterve helps patients connect with recruiting studies.
A Phase 2 trial (NCT06527222) is testing ranolazine vs placebo for muscle cramps in ALS—recruiting at UCSF, University of Florida, KU Medical Center (Fairway & Wichita), University of Missouri, and Ohio State. Learn eligibility, locations, and how to find ALS trials near you via Corterve.
Three actively recruiting U.S. colorectal cancer trials: ctDNA-guided AMB-05X after curative treatment (Houston, NCT06617858), dual checkpoint + SBRT for MSS/pMMR liver mets (Boston, NCT07128355), and intraperitoneal oxaliplatin/5FU for peritoneal metastases (Columbus & Dallas, NCT06269978). Learn eligibility, locations, and how to find CRC trials via Corterve.
A Phase 1 trial (NCT06462365) is testing TRX-103 (single post-HSCT infusion) for preventing GvHD in patients with hematologic malignancies undergoing mismatched stem cell transplants. Recruiting at City of Hope (CA), Dana-Farber (MA), University of Minnesota (MN), MSKCC (NY), and Fred Hutch (WA). Learn eligibility, locations, and how to find trials via Corterve.
A Phase 4 trial (NCT06143631, PLUM Study) is testing letrozole versus placebo for symptomatic uterine fibroids (leiomyoma). Recruiting at UCLA, UCSF, Mayo Clinic, University of Mississippi, and Duke. Learn eligibility, locations, and how to find fibroid trials near you via Corterve.
A Phase 2 trial (NCT06111781, SUGAR Study) is testing SBRT alone vs SBRT + oral Relugolix for clinicogenomic unfavorable intermediate-risk prostate cancer. Recruiting at Yale (New Haven, CT), MSKCC (New York, NY), and University of Washington (Seattle). Learn eligibility, locations, and how to find prostate cancer trials near you via Corterve.
A Phase 2 trial (NCT07384975) is testing NAV-240 (IV therapy) vs placebo for moderate-to-severe Hidradenitis Suppurativa (HS). Recruiting at multiple sites in Arizona, Florida, Kentucky, New Hampshire, and New York. Learn eligibility, locations, and how to find HS trials near you via Corterve.
A trial at UW Carbone Cancer Center is testing ultra-short whole breast irradiation (5 visits) with simultaneous integrated boost for early-stage breast cancer. Learn about this and other de-escalation radiation trials recruiting now.
A Phase 4 trial at University of Michigan is testing upadacitinib + corticosteroids vs steroids alone for acute severe ulcerative colitis (ASUC). Learn about this and other recruiting UC trials, eligibility, and how to find a study near you.
New clinical trials are testing advanced therapies for food allergies—including weight-based omalizumab dosing, combination immunotherapies, and microbiome approaches. Learn what's recruiting and how to find a trial near you.
A trial at UW Carbone Cancer Center is testing ultra-short whole breast irradiation (5 visits) with simultaneous integrated boost for early-stage breast cancer. Learn about this and other de-escalation radiation trials recruiting now.
A Phase 4 trial at University of Michigan is testing upadacitinib + corticosteroids vs steroids alone for acute severe ulcerative colitis (ASUC). Learn about this and other recruiting UC trials, eligibility, and how to find a study near you.
New clinical trials are testing advanced therapies for food allergies—including weight-based omalizumab dosing, combination immunotherapies, and microbiome approaches. Learn what's recruiting and how to find a trial near you.
High drop-out rates delay vital drug approvals. Discover actionable strategies to maximize patient engagement and build long-term trust in clinical research.
Traditional clinical trial matching is slow and highly exclusive. Learn how AI and precision medicine are streamlining the patient matching process to save lives.
Discover how shifting the focus toward patient centricity is transforming clinical trial design, accelerating recruitment, and improving retention rates.
📚 Our articles are based on peer-reviewed research, FDA announcements, and trusted healthcare sources including FDA.gov, ClinicalTrials.gov, Harvard Medical School, NIH, and leading medical journals.
Get the latest clinical trial news, FDA approvals, and breakthrough research delivered to your inbox weekly.
We respect your privacy. Unsubscribe at any time.
